Journal article

Evaluation of the safety of intravesical BCG therapy in France: analysis of serious adverse events notified over a three-year period

Objectives: Intravesical BCG therapy remains the first-line prophylactic treatment for recurrences of superficial bladder tumours. However necessary the safety, of this medicinal product, for which a potential risk of complications was demonstrated during development, needs to be evaluated.


  • There is no available fulltext. Please contact the lab or the authors.

Related material